Zhejiang Yatai Pharmaceutical Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Jianwei Cen

Chief executive officer

CN¥507.6k

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	2.6yrs
Board average tenure	2.6yrs

Recent management updates

Recent updates

CEO

Jianwei Cen (52 yo)

less than a year

Tenure

CN¥507,600

Compensation

Mr. Jianwei Cen is General Manager of Zhejiang Yatai Pharmaceutical Co. Ltd. from February 7, 2024. Mr. Cen was Deputy General Manager of Zhejiang Yatai Pharmaceutical Co. Ltd.from April 15, 2022 to Febru...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jianwei Cen	General Manager	less than a year	CN¥507.60k	no data
Jingyang Xu	Financial Director & Accounting Supervisor	2.6yrs	CN¥487.20k	no data
Wei Xu	Board Secretary	2.6yrs	CN¥487.40k	no data
Bao Kun Hu	Deputy General Manager	16.9yrs	CN¥404.00k	no data
Qin Shui Tan	Deputy General Manager	10.9yrs	CN¥453.60k	no data

2.6yrs

Average Tenure

52yo

Average Age

Experienced Management: 002370's management team is considered experienced (2.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Min Tu	Supervisor	2.7yrs	no data	no data
Xiaoming Huang	Director	2.6yrs	CN¥1.04m	no data
Cai Fu	Vice Chairman of the Board	2.6yrs	no data	no data
Lingbo Song	Non-Independent Director	2.6yrs	no data	no data
Wei Huang	Non-Independent Director	2.6yrs	CN¥359.60k	no data
Yajian Zhou	Non-Independent Director	2.6yrs	CN¥306.20k	no data
Haizhou Lu	Independent Director	2.6yrs	CN¥100.00k	no data
Yuehui Liu	Independent Director	2.6yrs	CN¥100.00k	no data
Lingjie Song	Chairman	2.6yrs	no data	no data
Min Cai	Independent Director	2.6yrs	CN¥100.00k	no data
Huaying Zhou	Supervisor	2.6yrs	no data	no data

2.6yrs

Average Tenure

49yo

Average Age

Experienced Board: 002370's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Zhejiang Yatai Pharmaceutical Management

Management criteria checks 2/4

Key information

Recent management updates

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

High number of new and inexperienced directors

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2022

High number of new and inexperienced directors

Zhejiang Yatai Pharmaceutical Co., Ltd. Announces Executive Appointments

Recent updates

Third quarter 2024 earnings released: CN¥0.012 loss per share (vs CN¥0.028 loss in 3Q 2023)

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Share price stability

Ningbo Heyi Culture Media Co., Ltd agreed to acquire Shanghai Xingaofeng Newsummit Biopharma Co., Ltd. from Zhejiang Yatai Pharmaceutical Co., Ltd. (SZSE:002370) for CNY 1.4 million.

Second quarter 2024 earnings released: EPS: CN¥0.018 (vs CN¥0.049 in 2Q 2023)

New minor risk - Share price stability

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

First quarter 2024 earnings released: CN¥0.005 loss per share (vs CN¥0.005 loss in 1Q 2023)

Full year 2023 earnings released: CN¥0.02 loss per share (vs CN¥0.25 loss in FY 2022)

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

New minor risk - Share price stability

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: CN¥0.028 loss per share (vs CN¥0.05 loss in 3Q 2022)

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: EPS: CN¥0.049 (vs CN¥0.05 loss in 2Q 2022)

Full year 2022 earnings released: CN¥0.25 loss per share (vs CN¥0.43 loss in FY 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.10 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.04 loss in 2Q 2021)

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2022

First quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.04 loss in 1Q 2021)

High number of new and inexperienced directors

Zhejiang Yatai Pharmaceutical Co., Ltd. Announces Executive Appointments

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: CN¥0.10 loss per share (vs CN¥0.098 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.05 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.05 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥3.86 loss in FY 2019)

Zhejiang Yatai Pharmaceutical Co., Ltd.(XSEC:002370) dropped from S&P Global BMI Index

New 90-day high: CN¥5.45

New 90-day low: CN¥3.60

New 90-day low: CN¥4.29

New 90-day low: CN¥4.44

New 90-day low: CN¥4.77

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

Earnings released

New 90-day high - CN¥6.25

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age